-
公开(公告)号:US20230139597A1
公开(公告)日:2023-05-04
申请号:US17858917
申请日:2022-07-06
申请人: ARDELYX, INC.
发明人: Jianhua Chao , Rakesh Jain , Lily Hu , Jason Gustaf Lewis , Helene Baribault , Jeremy Caldwell
IPC分类号: C07D471/08 , C07D493/08 , C07D413/14 , C07F9/6558 , C07D417/14 , C07D413/12
摘要: The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, A, X1, X2, R1, R2, and R3 are described herein.
-
公开(公告)号:US20230139282A1
公开(公告)日:2023-05-04
申请号:US17795349
申请日:2021-02-02
申请人: Manuel DE LERA RUIZ , Paola FAVUZZA , Zhuyan GUO , Bin HU , Michael J. KELLY, III , Zhiyu LEI , John A. MCCAULEY , David B. OLSEN , Brad SLEEBS , Tony TRIGLIA , Dongmei ZHAN , Lianyun ZHAO , Merck Sharp & Dohme LLC , The Walter and Eliza Hall Institute of Medical Research , MSD R&D (China) Co., Ltd.
发明人: Manuel de Lera Ruiz , Paola Favuzza , Zhuyan Guo , Bin Hu , Michael J. Kelly, III , Zhiyu Lei , John A. McCauley , David B. Olsen , Brad Sleebs , Tony Triglia , Dongmei Zhan , Lianyun Zhao
IPC分类号: A61K31/513 , A61K45/06 , C07D405/12 , C07D233/88 , C07D405/14 , C07D417/14 , C07D491/18 , A61P33/06 , A61K31/529 , A61K31/5377 , C07D401/06
摘要: Provided are methods of treating malaria comprising administration of compounds of Formula (I) or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein the variables are as defined herein. Also provided are uses of the compounds of Formula (I), as defined herein, for treating a Plasmodium infection, and for treating malaria. Also provided are methods of treatment further comprising administration of one or more additional anti-malarial compounds.
-
公开(公告)号:US20230138480A1
公开(公告)日:2023-05-04
申请号:US17965145
申请日:2022-10-13
IPC分类号: A61K31/541 , A61P35/04 , A61K31/427 , A61K31/4409 , A61K31/4425 , A61K31/4439 , A61K31/4709 , A61K31/496 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D277/46 , C07D417/04 , C07D417/10 , C07D417/14
摘要: The present disclosure features compounds useful for the treatment of BAF complex-related disorders.
-
公开(公告)号:US20230134932A1
公开(公告)日:2023-05-04
申请号:US17822337
申请日:2022-08-25
IPC分类号: C07D417/14 , C07D417/12
摘要: The present invention provides compounds inhibiting eIF4E activity, and compositions and methods of using thereof.
-
公开(公告)号:US20230131830A1
公开(公告)日:2023-04-27
申请号:US17802307
申请日:2021-03-03
发明人: Chun-Ping Chang , Ya-Hui Chi , Chiung-Tong Chen , Chuan Shih , Yi-Yu Ke
IPC分类号: C07D403/14 , C07D417/14 , C07D405/14 , C07D401/14 , A61P35/00 , A61P11/00 , C07D413/14 , C07D487/08 , C07D403/12
摘要: Pyrimidine compounds of Formula (I). Assignments to the variables in the formula are set forth herein. Also disclosed is a method of treating cancer with one of the pyrimidine compounds.
-
6.
公开(公告)号:US20230131465A1
公开(公告)日:2023-04-27
申请号:US17941860
申请日:2022-09-09
发明人: Kai Gerlach , Daniela Gavina Berta , Marco Ferrara , Kirsten Gutsche , Ursula Mueller-Vieira , Scott Hobson , Frank Runge , Graeme Semple , Viktor Vintonyak , Yifeng Xiong
IPC分类号: A61K31/497 , C07D403/14 , C07D487/08 , C07D417/14 , A61K45/06 , A61K31/433
摘要: The invention relates to 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) which are agonists of GPR52, useful in treating central nervous system diseases and other diseases.
In addition, the invention relates to the 3-phenoxyazetidin-1-yl-heteroaryl pyrrolidine derivatives of general formula (I) for use as a medicament, pharmaceutical compositions comprising at least a compound of general formula (I) and processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.-
公开(公告)号:US20230129944A1
公开(公告)日:2023-04-27
申请号:US17983747
申请日:2022-11-09
IPC分类号: C07D487/04 , C07D401/14 , C07D413/14 , C07D403/14 , C07D417/14 , C07D403/04 , A61K31/53 , A61K31/5377 , A61K45/06 , A61K31/496
摘要: Compounds and compositions useful for treating disorders related to mutant KIT are described herein.
-
公开(公告)号:US20230128162A1
公开(公告)日:2023-04-27
申请号:US17790358
申请日:2022-02-17
发明人: Yuki TACHIBANA , Shota UEHARA , Yuto UNOH , Kenji NAKAHARA , Yoshiyuki TAODA , Koji KASAMATSU , Yukiko YAMATSU , Shigeru ANDO , Atsuhiro IIMURO , Takahiro SUTO , Michihito SASAKI
IPC分类号: C07D401/14 , C07D401/06 , C07D405/14 , C07D409/14 , C07D413/14 , C07D471/04 , C07D495/04 , C07D403/06 , C07D403/14 , C07D417/14 , C07D401/04 , C07D417/06 , C07D498/04 , A61P31/14 , C07D487/04
摘要: The present invention provides a compound exhibiting coronavirus 3CL protease inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising the same. Furthermore, the present invention provides a crystalline form useful as an active pharmaceutical ingredient, and a pharmaceutical composition comprising the same.
A compound represented by Formula (I): wherein Y is N or the like; R1 is substituted or unsubstituted aromatic heterocyclyl or the like; R2 is substituted or unsubstituted aromatic carbocyclyl or the like; R3 is substituted or unsubstituted aromatic heterocyclyl or the like; —X— is —NH— or the like; m is 1 or the like; R5a is each independently a hydrogen atom or the like; R5b is each independently a hydrogen atom or the like; n is 1 or the like; R4a is each independently a hydrogen atom or the like; and R4b is each independently a hydrogen atom or the like, or a pharmaceutically acceptable salt thereof.-
公开(公告)号:US20230127046A1
公开(公告)日:2023-04-27
申请号:US17756275
申请日:2020-11-26
申请人: RIKEN , TOKYO UNIVERSITY OF PHARMACY AND LIFE SCIENCES , MICROBIAL CHEMISTRY RESEARCH FOUNDATION
发明人: Tatsunobu SUMIYA , Yosuke NISHIGAYA , Ryosuke NAMIE , Noriaki HASHIMOTO , Akihiro ITO , Fumiyuki SHIRAI , Ko KIKUZATO , Minoru YOSHIDA
IPC分类号: C07D209/42 , C07D401/12 , C07D403/12 , C07D417/14 , C07D471/04
摘要: A compound represented by the general formula (I) given below or a pharmacologically acceptable salt thereof has been found to have a strong G9a inhibitory effect. The compound (I) or the pharmacologically acceptable salt thereof inhibits G9a and thereby has high usefulness for the treatment, prevention or suppression of various pathological conditions (proliferative disease such as cancer, β-globin abnormality, fibrosis, pain, neurodegenerative disease, Prader-Willi syndrome, malaria, viral infection, myopathy, autism, etc.).
-
公开(公告)号:US11634447B2
公开(公告)日:2023-04-25
申请号:US17120441
申请日:2020-12-14
发明人: Yeeman K. Ramtohul , Sanjoy Kumar Das , Caroline Cadilhac , Thumkunta Jagadeeswar Reddy , Louis Vaillancourt , Michel Gallant , Bingcan Liu , Evelyne Dietrich , Frederic Vallee , Julien Martel , Carl Poisson
IPC分类号: A61K31/706 , A61K31/7064 , C07H7/02 , C07D413/14 , C07D407/14 , C07D495/04 , C07D405/14 , C07D309/10 , C07H15/26 , C07D409/14 , C07H19/056 , C07D417/14 , A61P31/04 , C07H7/04 , C07H7/06 , C07H19/02 , A61K31/7028 , A61K31/7034 , A61K31/7036 , A61K31/7042 , A61K31/7048 , A61K31/7056
摘要: The present invention relates to compounds useful for the treatment or prevention of bacteria infections. These compounds have formula I: The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. Finally, the invention provides processes for making compounds of the invention.
-
-
-
-
-
-
-
-
-